Trial Profile
A study of HLX06 to treat solid tumors.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 23 Apr 2018
Price :
$35
*
At a glance
- Drugs Vulinacimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 23 Apr 2018 New trial record
- 24 Jan 2018 According to a Henlius Biotech media release, the company has received official approval from China Food and Drug Administration to conduct clinical trials for HLX06 to treat solid tumors.